Who are Placebo to match deucravacitinib's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leqselvi, Sotyktu, In open-label phase: treatment with tofacitinib, JAK Inhibitor, Janus Kinase Inhibitor, GSK2340274A.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-to-match-deucravacitinib.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Placebo to match deucravacitinib — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo to match deucravacitinib (Placebo to match deucravacitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: TYK2 inhibitor. Area: Immunology.

phase 3 TYK2 inhibitor TYK2 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Placebo to match deucravacitinib (Placebo to match deucravacitinib) — Takeda. Deucravacitinib is a small molecule that acts as a selective tyrosine kinase 2 (TYK2) inhibitor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Placebo to match deucravacitinib TARGET	Placebo to match deucravacitinib	Takeda	phase 3	TYK2 inhibitor	TYK2
Leqselvi	DEURUXOLITINIB	Sun Pharm Inds Inc	marketed		JAK1, JAK2, TYK2	2024-01-01
Sotyktu	DEUCRAVACITINIB	Bristol-Myers Squibb	marketed	Tyrosine Kinase 2 Inhibitor [EPC]	Non-receptor tyrosine-protein kinase TYK2	2022-01-01
In open-label phase: treatment with tofacitinib	in-open-label-phase-treatment-with-tofacitinib	Pfizer	marketed	Janus kinase inhibitor	Janus kinase 1 (JAK1), Janus kinase 3 (JAK3), and tyrosine kinase 2 (TYK2)
JAK Inhibitor	JAK Inhibitor	Fred Hutchinson Cancer Center	marketed	JAK inhibitor	JAK1, JAK2, JAK3, and/or TYK2
Janus Kinase Inhibitor	Janus Kinase Inhibitor	Peking Union Medical College Hospital	marketed	Janus Kinase Inhibitor	JAK1, JAK2, JAK3, TYK2
GSK2340274A	GSK2340274A	GlaxoSmithKline	phase 3	TYK2 inhibitor	TYK2 (tyrosine kinase 2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (TYK2 inhibitor class)

GlaxoSmithKline · 6 drugs in this class
Takeda · 1 drug in this class
UMN Pharma Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo to match deucravacitinib — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-to-match-deucravacitinib. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab